Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Hot Topics of the Day|PHGKB
Search PHGKB:


Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
173 hot topic(s) found with the query "Cystic fibrosis"

Cystic Fibrosis Patient Asks for Increased Efforts Around Antibiotic Resistance
Pew Trust, January 28, 2020 (Posted: Feb-03-2020 9AM)

I am living with cystic fibrosis, and many of us with the condition rely on antibiotics every day. In the CF world, antibiotic resistance is commonplace. It is one of the leading complications that contribute to patient death.

Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy.
Trapnell Bruce C et al. Chronic respiratory disease 171479973119900612 (Posted: Jan-29-2020 7AM)

We investigated the relationship between self-reported adherence to pancreatic enzyme replacement therapy (PERT), nutritional status, and all-cause hospitalization in cystic fibrosis (CF) patients with a record of PERT use.

Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure
HS Hayden et al, Nature Medicine, January 20, 2020 (Posted: Jan-21-2020 9AM)

We identified an early, progressive fecal dysbiosis that distinguished infants with CF and low length from infants with CF and normal length. This dysbiosis included altered abundances of taxa that perform functions that are important for GI health, nutrient harvest and growth hormone signaling,

Should We Sequence the Genome of Every Newborn?
Scientific American Blog, December 2019 (Posted: Jan-04-2020 2PM)

Thankfully, we already have a model for how to do this: newborn screening programs such as those run by state departments of public health in the U.S., which test a drop of blood taken from each baby’s heel for several dozen conditions, including cystic fibrosis and sickle cell anemia.

Persistence pays off in treatment for cystic fibrosis
The Washington Post, November 23, 2019 (Posted: Nov-25-2019 8AM)

The achievement is the result of persistence by patient advocates and scientists, who never threw in the towel, even when the goal seemed impossible. A lot of bake sales went into supporting the quest, and that kind of support is priceless.

Fulfilling the Promise - Ensuring the Success of Newborn Screening throughout Life
CDC, November 2019 Brand (Posted: Nov-13-2019 8AM)

Each year, more than 13,000 newborn babies are identified with conditions such as cystic fibrosis, sickle cell disease, congenital heart defects, and hearing loss through a public health program called newborn screening. Without specialized care and treatment, these babies would face long-term disability, or even death.

Cystic Fibrosis Diagnosis in Newborns, Children, and Adults.
Castellani Carlo et al. Seminars in respiratory and critical care medicine 2019 Nov (Posted: Nov-06-2019 8AM)

The diagnosis of cystic fibrosis (CF) has traditionally relied on the presence of clinical features of the disease. Today, diagnosis through newborn screening (NBS) is becoming the standard of modern care. NBS programs can identify CF prior to clinical presentation, but a scrupulous system must be in place to ensure all steps in the program are performing

Cystic fibrosis: triple therapy shows promising results
E Mahase, BMJ, November 4, 2019 (Posted: Nov-05-2019 8AM)

The triple therapy Trikafta (elexacaftor, tezacaftor, and ivacaftor) has the potential to lead to “transformative improvements in the lives of people with cystic fibrosis,” two phase III trials indicate. The studies looked at the efficacy and safety of Trikafta in patients with one copy of Phe508del—the most common gene mutation for cystic fibrosis.

Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis.
Collins Francis S et al. The New England journal of medicine 2019 Oct (Posted: Nov-04-2019 8AM)

The journey to gene-based therapies for cystic fibrosis began with enthusiasm over the prospect of gene therapy. But the challenges of using gene transfer to achieve long-lasting correction in the airway proved daunting.

FDA approves new breakthrough therapy for cystic fibrosis- Treatment approved for approximately 90% of patients with cystic fibrosis, many of whom had no approved therapeutic options
FDA News Release, October 2019 (Posted: Nov-03-2019 8AM)

Studies Yield ‘Impressive’ Results in Fight Against Cystic Fibrosis
N Chokshi, NY Times, October 31, 2019 (Posted: Nov-03-2019 8AM)

A pair of new studies report “impressive” benefits from a drug therapy for cystic fibrosis, a deadly and devastating disease that affects tens of thousands of people worldwide. These findings indicate that it may soon be possible to offer safe and effective molecularly targeted therapies to 90 percent of persons with cystic fibrosis.

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
HGM Heijerman et al, Lancet, October 31, 2019 (Posted: Nov-03-2019 7AM)

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
PJ Middleton et al, NEJM, October 31, 2019 (Posted: Nov-03-2019 7AM)

New Hope For Patients Living With Cystic Fibrosis After Scientists Unveil Therapy
NPR, November 1, 2019 (Posted: Nov-02-2019 7AM)

NPR's Mary Louise Kelly talks with National Institutes of Health director Dr. Francis Collins about the new cystic fibrosis drug therapy that could benefit 90% of patients with the disease.

Dare to Dream: The Long Road to Targeted Therapies for Cystic Fibrosis
NIH Director's Blog, October 31, 2019 Brand (Posted: Nov-01-2019 9AM)

Today, I’m overjoyed to say that this dream finally appears to have come true for about 90 percent of people with CF. Two international teams, including researchers report impressive results from phase 3 clinical trials of a triple drug therapy for individuals with CF and at least one copy of Phe508del, the most common CF-causing mutation.

The future of cystic fibrosis care: a global perspective.
Bell Scott C et al. The Lancet. Respiratory medicine 2019 Sep (Posted: Oct-16-2019 6AM)

The Lancet Respiratory Medicine Commission on the future of cystic fibrosis care was established at a time of great change in the clinical care of people with the disease, with a growing population of adult patients, widespread genetic testing supporting the diagnosis of cystic fibrosis, and the development of therapies.

Scotland strikes deal to offer cystic fibrosis drugs
B Christie, BMJ, September 13, 2019 (Posted: Sep-13-2019 10AM)

Creating genetic reports that are understood by nonspecialists: a case study.
Recchia Gabriel et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Sep (Posted: Sep-12-2019 7AM)

The study investigated the feasibility of creating reports for cystic fibrosis carrier testing through a rapid user-centered design process that built on a previously developed generic template. The authors evaluated the new reports’ communication efficacy and effects on comprehension against comparable reports used in current clinical practice.

Thirtieth Anniversary of Cystic Fibrosis Gene Discovery
Francis Collins, NIH Director's blog, August 2019 Brand (Posted: Sep-08-2019 2PM)

In 1989, the gene that causes cystic fibrosis, was discovered by a collaborative research effort involving the University of Michigan, Ann Arbor, and colleagues at the Hospital for Sick Children, Toronto. This year marks the 30th anniversary of the discovery, which has yielded life-sustaining targeted therapies for many kids born with this rare disease.

Predictive value of genomic screening: cross-sectional study of cystic fibrosis in 50,788 electronic health records
JP Sugunarajav et al, NPJ Genomic Medicine, September 5, 2019 (Posted: Sep-06-2019 7AM)

Despite EHR-based phenotyping limitations, the presence or absence of pathogenic CFTR variants has strong predictive value for CF diagnosis when EHR data is used as the sole phenotyping source.

Prenatal genetic testing for cystic fibrosis: a systematic review of clinical effectiveness and an ethics review.
Kessels Sharon J M et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Aug (Posted: Sep-01-2019 7AM)

To determine effectiveness, this study conducted a systematic literature review whose protocol outlined search strategies across eight databases, study inclusion criteria, and prespecified literature screening, data extraction, and synthesis processes. The authors conducted a scoping search on ethical considerations

Vertex sinks on reports of deaths of patients taking cystic fibrosis drug
D Garde, Stat News, August 28, 2019 (Posted: Aug-30-2019 7AM)

Making precision medicine personal for cystic fibrosis
C Manfredi et al, Science, July 19, 2019 (Posted: Jul-19-2019 1PM)

On the basis of classifying CFTR mutant proteins, cystic fibrosis has been viewed as a model for personalized therapeutics. However, CFTR variants may have pleiotropic effects, which complicates assignment of specifically tailored drugs to discrete mechanisms In addition, the cost of new CFTR modulators constrains reimbursement and has delayed drug availability for certain patient groups

Cystic Fibrosis Patients Turn to Experimental Phage Therapy
A Ellin, NY Times, May 17, 2019 (Posted: May-18-2019 0PM)

Sequencing as a first-line methodology for cystic fibrosis carrier screening
KA Beauchamp et al, Genetics in Medicine, April 30, 2019 (Posted: Apr-30-2019 8AM)

Five Feet Apart
CF Foundation, March 2019 (Posted: Mar-17-2019 4PM)

Scientists find new approach that shows promise for treating cystic fibrosis
NIH, March 13, 2019 Brand (Posted: Mar-14-2019 10AM)

Health economic modelling in Cystic Fibrosis: A systematic review.
Mohindru Bishal et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2019 Feb (Posted: Feb-12-2019 10AM)

Outrage as cystic fibrosis drug firm posts big profit
The Observer, February 10, 2019 (Posted: Feb-10-2019 1PM)

‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress
A Joseph, Stat News, February 4, 2019 (Posted: Feb-04-2019 8AM)

The increasing challenge of genetic counseling for cystic fibrosis.
Foil Kimberly E et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018 Dec (Posted: Dec-19-2018 10AM)

New therapies pack a triple-drug punch to treat cystic fibrosis
A Cunningham, Science News, October 19, 2018 (Posted: Oct-21-2018 2PM)

Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis.
Smith Daniel J et al. Gene 2018 Oct 12-17 (Posted: Oct-21-2018 2PM)

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
D Keating et al, NEJM, October 18, 2018 (Posted: Oct-19-2018 4PM)

Triple CFTR Modulator Therapy for Cystic Fibrosis
F Holguin, NEJM, October 18, 2018 (Posted: Oct-19-2018 4PM)

Cystic fibrosis survival: the changing epidemiology.
Corriveau Sophie et al. Current opinion in pulmonary medicine 2018 Nov 24(6) 574-578 (Posted: Oct-10-2018 7AM)

Clinical outcomes in U.S. infants with cystic fibrosis from 2001 to 2012.
Hoch Heather et al. Pediatric pulmonology 2018 Sep (Posted: Oct-03-2018 8AM)

Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
Vadagam Pratyusha et al. Journal of managed care & specialty pharmacy 2018 Oct 24(10) 987-997 (Posted: Sep-26-2018 10AM)

When should genomic testing be considered for cystic fibrosis?
Wysocki Kenneth et al. Journal of the American Association of Nurse Practitioners 2018 Sep 30(9) 478-479 (Posted: Sep-19-2018 9AM)

V232D mutation in patients with cystic fibrosis: Not so rare, not so mild.
Fernández-Lorenzo Ana E et al. Medicine 2018 Jul 97(28) e11397 (Posted: Jul-18-2018 9AM)

A Drug Costs $272,000 a Year. Not So Fast, Says New York State.
K Thomas, New York Times, June 19, 2018 (Posted: Jun-26-2018 7PM)

Evaluating the Impact of Precision Medicine: How Ivacaftor Reduces Hospitalizations of Patients with Cystic Fibrosis
RF Green al, CDC Blog Post, May 8, 2018 Brand (Posted: May-08-2018 5PM)

Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis–Related Hospitalizations
LB Feng et al, Health Affairs, May 2018 (Posted: May-08-2018 8AM)

Disease-modifying genetic factors in cystic fibrosis.
Marson Fernando A L et al. Current opinion in pulmonary medicine 2018 May (3) 296-308 (Posted: May-04-2018 11AM)

Cystic Fibrosis Disease Modifiers: Complex Genetics Defines the Phenotypic Diversity in a Monogenic Disease.
O'Neal Wanda K et al. Annual review of genomics and human genetics 2018 Apr (Posted: May-04-2018 11AM)

The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.
Eckford Paul D W et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018 Apr (Posted: May-02-2018 9AM)

Transition from paediatric to adult healthcare for young people with cystic fibrosis: Parents' information needs.
Coyne Imelda et al. Journal of child health care : for professionals working with children in the hospital and community 2018 Jan 1367493518768448 (Posted: Apr-10-2018 9AM)

Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations.
Schmidt Masja et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018 Mar (Posted: Mar-27-2018 1PM)

Nutritional Status the First Two Years of Life in Cystic Fibrosis Diagnosed by Newborn Screening.
Munck Anne et al. Journal of pediatric gastroenterology and nutrition 2018 Mar (Posted: Mar-21-2018 4PM)

ECFS best practice guidelines: the 2018 revision.
Castellani Carlo et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018 Mar (Posted: Mar-07-2018 9AM)

Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era.
Wiencek Joesph R et al. Clinical chemistry 2018 Feb (Posted: Feb-14-2018 11AM)

Cystic Fibrosis and C. Diff : A Dangerous Combination
CDC Safe Healthcare Blog Post, 2017 Brand (Posted: Feb-07-2018 0PM)

An update on new and emerging therapies for cystic fibrosis.
Hudock Kristin M et al. Expert opinion on emerging drugs 2017 Dec (4) 331-346 (Posted: Feb-07-2018 0PM)

Translational research to enable personalized treatment of cystic fibrosis.
Hagemeijer Marne C et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017 Dec (Posted: Feb-07-2018 0PM)

Cystic Fibrosis: Lungs’ Bacterial Population Changes in the First Few Years of Life
Frontline Genetics, Feb 7, 2018 (Posted: Feb-07-2018 11AM)

Personalized Medicine in CF: From Modulator Development to Therapy for Cystic Fibrosis Patients with Rare CFTR Mutations.
Harutyunyan Misak et al. American journal of physiology. Lung cellular and molecular physiology 2017 Dec (Posted: Jan-24-2018 10AM)

Does distance to a cystic fibrosis center impact health outcomes?
Johnson Ben et al. Pediatric pulmonology 2018 Jan (Posted: Jan-24-2018 10AM)

Cystic fibrosis: Discovery of a key molecule for improving treatments
Frontiers Blog, Dec 20, 2017 (Posted: Dec-20-2017 9AM)

Treating Specific Variants Causing Cystic Fibrosis.
Cutting Garry R et al. JAMA 2017 Dec (21) 2130-2131 (Posted: Dec-12-2017 11AM)

Health of people with cystic fibrosis shows positive trends in US and Canada
Check Orphan, Nov 22, 2017 (Posted: Nov-23-2017 11AM)

CFTR Modulator Therapy for Cystic Fibrosis.
Grasemann Hartmut et al. The New England journal of medicine 2017 Nov (Posted: Nov-20-2017 8AM)

Roadmap for an early gene therapy for cystic fibrosis airway disease.
Carlon Marianne S et al. Prenatal diagnosis 2017 Oct (Posted: Nov-15-2017 9AM)

A comparison of two approaches to education about carrier testing for cystic fibrosis.
Leonard K P et al. Journal of genetic counseling 1995 Jun 4(2) 97-113 (Posted: Aug-30-2017 9AM)

A survey of reimbursement for cystic fibrosis carrier testing.
Bernhardt B A et al. Journal of genetic counseling 1993 Jun 2(2) 69-76 (Posted: Aug-30-2017 9AM)

A New Targeted CFTR Mutation Panel Based on Next-Generation Sequencing Technology.
Lucarelli Marco et al. The Journal of molecular diagnostics : JMD 2017 Jul (Posted: Jul-26-2017 9AM)

New Vertex drugs show dramatic gains for tough-to-treat cystic fibrosis patients
A Feuerstein, StatNews, July 18, 2017 (Posted: Jul-18-2017 4PM)

Cystic Fibrosis DNA Mutation Detection Proficiency Testing
CDC Division of Laboratory Systems, 2017 Brand (Posted: Jul-11-2017 11AM)

FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis
FDA, May 2017 (Posted: Jul-11-2017 10AM)

Expanded Cystic Fibrosis Therapy
News from FDA, JAMA, July 4, 2017 (Posted: Jul-07-2017 10PM)

Cystic Fibrosis Among Asians: Why Ethnicity-Based Genetic Testing is Obsolete
R Lewis, PLOS Blogs, July 6, 2017 (Posted: Jul-06-2017 5PM)

Genetic Carrier Screening in the Twenty-first Century.
Yao Ruofan et al. Clinics in laboratory medicine 2016 Jun 36(2) 277-88 (Posted: Jun-07-2017 9AM)

The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
Grosse Scott D et al. The Milbank quarterly 2016 Jun 94(2) 366-91 (Posted: May-17-2017 9AM)

Genomic sequencing in cystic fibrosis newborn screening: what works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing?
Currier Robert J et al. Genetics in medicine : official journal of the American College of Medical Genetics 2017 May (Posted: May-10-2017 10AM)

Refining the continuum of CFTR-associated disorders in the era of newborn screening.
Levy H et al. Clinical genetics 2016 May 89(5) 539-49 (Posted: May-10-2017 10AM)

Genomic sequencing in cystic fibrosis newborn screening: what works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing?
RJ Currier et al, Genetics in Medicine, May 4, 2017 (Posted: May-04-2017 3PM)

Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis.
Hayeems Robin Z et al. The Journal of pediatrics 2017 Mar (Posted: Mar-15-2017 8AM)

'Stunning’ gap: Canadians with cystic fibrosis outlive Americans by a decade
E Boodman, Stat News, March 14, 2017 (Posted: Mar-15-2017 6AM)

Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis.
Villate-Beitia Ilia et al. Drug development and industrial pharmacy 2017 Mar 1-11 (Posted: Mar-14-2017 8AM)

Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study
AL Stephenson et al, Ann Int Medicine March 13, 2017 (Posted: Mar-14-2017 8AM)

Ethnicity impacts the cystic fibrosis diagnosis: A note of caution.
Bosch Barbara et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017 Feb (Posted: Mar-01-2017 10AM)

Diagnosis of Cystic Fibrosis in Nonscreened Populations.
Sosnay Patrick R et al. The Journal of pediatrics 2017 Feb 181SS52-S57.e2 (Posted: Feb-01-2017 11AM)

Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis.
Ren Clement L et al. The Journal of pediatrics 2017 Feb 181SS45-S51.e1 (Posted: Feb-01-2017 11AM)

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.
Farrell Philip M et al. The Journal of pediatrics 2017 Feb 181SS4-S15.e1 (Posted: Feb-01-2017 11AM)

Diagnosis of Cystic Fibrosis in Screened Populations.
Farrell Philip M et al. The Journal of pediatrics 2017 Feb 181SS33-S44.e2 (Posted: Feb-01-2017 11AM)

Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.
Sosnay Patrick R et al. The Journal of pediatrics 2017 Feb 181SS27-S32.e1 (Posted: Feb-01-2017 11AM)

Cystic Fibrosis Diagnostic Challenges over 4 Decades: Historical Perspectives and Lessons Learned.
Farrell Philip M et al. The Journal of pediatrics 2017 Feb 181SS16-S26 (Posted: Feb-01-2017 11AM)

The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe.
Barben Jürg et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2016 Dec (Posted: Jan-11-2017 9AM)

Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy.
Elborn J Stuart et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2016 Dec (Posted: Dec-21-2016 10AM)

Associations between genetics, medical status, physical exercise and psychological well-being in adults with cystic fibrosis.
Backström-Eriksson Lena et al. BMJ open respiratory research 2016 3(1) e000141 (Posted: Dec-14-2016 0PM)

Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era.
Coffey Michael J et al. The Journal of pediatrics 2016 Nov (Posted: Nov-28-2016 9AM)

Babies with CF Not Diagnosed in Newborn Screenings Do More Poorly, Study Finds
J Fernandez, CF Foundation, November 18, 2016 (Posted: Nov-28-2016 9AM)

Cystic fibrosis: to screen or not to screen? Involving a Citizens' jury in decisions on screening carrier.
Mosconi Paola et al. Health expectations : an international journal of public participation in health care and health policy 2015 Dec 18(6) 1956-67 (Posted: Nov-16-2016 11AM)

New App for Cystic Fibrosis Patients Helps to Manage Symptoms
Global Genes, 2016 (Posted: Oct-08-2016 10AM)

Genetic medicines for CF: Hype versus reality.
Alton Eric W F W et al. Pediatric pulmonology 2016 Oct (S44) S5-S17 (Posted: Oct-08-2016 10AM)

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives.
Schmidt Béla Z et al. Clinical pharmacology : advances and applications 2016 127-140 (Posted: Oct-08-2016 10AM)

Cystic fibrosis: a clinical view.
Castellani Carlo et al. Cellular and molecular life sciences : CMLS 2016 Oct (Posted: Oct-08-2016 10AM)

CFTR pharmacology.
Zegarra-Moran Olga et al. Cellular and molecular life sciences : CMLS 2016 Oct (Posted: Oct-08-2016 10AM)

Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis.
Hayeems Robin Z et al. Pediatrics 2016 Aug (Posted: Aug-10-2016 9AM)

Non-invasive prenatal diagnosis for cystic fibrosis: detection of paternal mutations, exploration of patient preferences and cost analysis.
Hill Melissa et al. Prenatal diagnosis 2015 Oct 35(10) 950-8 (Posted: Aug-03-2016 9AM)

Toward quality improvement in cystic fibrosis newborn screening: Progress and continuing challenges.
Farrell Philip M et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2016 May (Posted: May-18-2016 10AM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.